Literature DB >> 9595039

Translocation (3;5)(q21;q34) in erythroleukemia: a molecular and in situ hybridization study.

Y L Kwong1.   

Abstract

Translocation (3;5) is an uncommon karyotypic aberration in acute myeloid leukemia (AML). With the exception of M3, t(3;5) has been reported in every other subtype of AML, being most frequently associated with AML M6. Although a variety of breakpoints have been described, it has been suggested that the breakpoints in t(3;5) of all the reported cases should be assigned to 3q25.1 and 5q34. Recently, the breakpoints in three pediatric cases of AML M2 with t(3;5) were cloned and shown to involve the myelodysplasia/myeloid leukemia factor I (MLF1) gene on 3q25.1 and the nucleophosmin (NPM) gene on 5q34, generating a chimeric NPM/MLF1 transcript. An adult case of indolent erythroleukemia was found on karyotypic analysis to have t(3;5)(q21;q34). In about 60% of cells, the translocation was unbalanced, resulting in loss of the der(3) chromosome, implying that the critical leukemogenic sequence might reside on the der(5) chromosome. Molecular analysis of this case, however, failed to show rearrangement of the NPM gene and an MLF1/NPM transcript. A review of other reported cases of AML M6 with t(3;5) showed that the commonest breakpoint on chromosome 3 was also assigned to 3q21, as in our case. The considerable clinical, pathologic, cytogenetic and molecular differences observed in AML with t(3;5) suggest that these cases might be heterogeneous.

Entities:  

Mesh:

Year:  1998        PMID: 9595039     DOI: 10.1016/s0165-4608(97)00366-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  1 in total

1.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.